These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 2046811

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ.
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA.
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [Abstract] [Full Text] [Related]

  • 8. [A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
    Shigematsu T, Kawaguchi Y, Unemura S, Suzuki M, Yamamoto H, Morita T, Momose M, Ogawa A, Nakayama M, Miyahara T.
    Nihon Jinzo Gakkai Shi; 1989 Apr; 31(4):393-401. PubMed ID: 2787433
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Influence of serum phosphate on the efficacy of oral 1,25-dihydroxyvitamin D3 pulse therapy.
    Shoji S, Nishizawa Y, Tabata T, Emoto M, Morita A, Goto H, Ishimaura E, Inoue T, Inaba M, Miki T.
    Miner Electrolyte Metab; 1995 Apr; 21(1-3):223-8. PubMed ID: 7565454
    [Abstract] [Full Text] [Related]

  • 11. [Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure].
    Matuszkiewicz-Rowińska J, Niemczyk S, Pacocha E, Puka J, Switalski M, Bogdańska-Straszyńska B, Ostrowski K.
    Pol Arch Med Wewn; 1996 Jul; 96(1):15-22. PubMed ID: 8966141
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effects of dietary phosphorus restriction on secondary hyperparathyroidism in hemodialysis patients during intermittent oral high-dose 1,25(OH)2D3 treatment.
    Tabata T, Shoji S, Morita A, Emoto M, Inoue T, Miki T, Nishizawa Y, Morii H.
    J Nutr Sci Vitaminol (Tokyo); 1991 Dec; 37 Suppl():S105-12. PubMed ID: 1820436
    [Abstract] [Full Text] [Related]

  • 14. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
    Liou HH, Chiang SS, Huang TP, Shieh SD, Akmal M.
    Miner Electrolyte Metab; 1994 Dec; 20(3):97-102. PubMed ID: 7816008
    [Abstract] [Full Text] [Related]

  • 15. Effect of intermittent oral 1,25(OH)2D3 therapy on bone Gla protein in dialysis patients.
    Miki T, Nakatsuka K, Nishizawa Y, Emoto M, Morita A, Tabata T, Matsushita Y, Inoue T, Morii H.
    Endocrinol Jpn; 1991 Oct; 38(5):479-83. PubMed ID: 1843267
    [Abstract] [Full Text] [Related]

  • 16. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
    Peng SJ, Yang CS, Ferng SH, Chen LY.
    Miner Electrolyte Metab; 1997 Oct; 23(1):13-8. PubMed ID: 9058364
    [Abstract] [Full Text] [Related]

  • 17. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
    Gadallah MF, Arora N, Torres C, Ramdeen G, Schaeffer-Pautz A, Moles K.
    Adv Perit Dial; 2000 Oct; 16():303-7. PubMed ID: 11045316
    [Abstract] [Full Text] [Related]

  • 18. Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.
    Brandi L, Daugaard H, Tvedegaard E, Storm T, Olgaard K.
    Nephron; 1989 Oct; 53(3):194-200. PubMed ID: 2797340
    [Abstract] [Full Text] [Related]

  • 19. Oral 1,25(OH)2D3 pulse therapy for the treatment of secondary hyperparathyroidism.
    Takahashi S, Okada K, Kinosita Y, Yanai M, Kuno T, Nagura Y.
    Nihon Jinzo Gakkai Shi; 1993 Apr; 35(4):377-82. PubMed ID: 8341016
    [Abstract] [Full Text] [Related]

  • 20. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L, Daugaard H, Nielsen PK, Jensen LT, Egsmose C, Olgaard K.
    Nephron; 1996 Apr; 74(1):89-103. PubMed ID: 8883025
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.